secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001104659-24-041549
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell reports FY2023 net loss of $17.2M; cash drops to $1.45M; awaits FDA SPA
--------------------------------------------------------------------------------

- Net loss $17.2M ($0.40/share) vs $24.3M ($0.66) in 2022; no revenue (pre-revenue biotech).
- Cash and equivalents $1.45M at Dec 31, 2023, down from $3M in 2022; raises going-concern risk.
- R&D expenses fell to $10.8M from $14M; headcount reduced ~30% in October 2023 strategic realignment.
- Submitted SPA request to FDA in Feb 2024 for Phase 3b trial of NurOwn in ALS; awaiting 45-day review.
- Withdrew BLA for NurOwn in Oct 2023 after FDA advisory committee voted against effectiveness evidence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924041549/0001104659-24-041549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924041549/tm2410297d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-041549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer